Pfizer : PFE

All Pfizer Articles

1465 Articles

Jon C. Ogg | Dec 4, 2013 at 11:55 AM EST

Meet the Preliminary 2014 Dogs of the Dow: Dividends Galore

ThinkstockThere is a trend at the end of each year followed by many income investors. This is the Dogs of…

Jon C. Ogg | Dec 3, 2013 at 8:50 AM EST

Top Analyst Upgrades and Downgrades: Apple, 3D Systems, Micron, Tesla and More

These are the top analyst upgrades, downgrades and initiations from select Wall Street research calls on Tuesday, December 3, 2013.…

Jon C. Ogg | Nov 19, 2013 at 11:50 AM EST

The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years

ThinkstockThe market for pharmaceuticals and biotech drugs just keeps growing. The so-called patent cliff may be affecting Big Pharma companies…

Jon C. Ogg | Nov 12, 2013 at 9:00 AM EST

Short Sellers Made Big Changes in High-Yield Dividend Stocks

Jon OggWe have now seen the short interest reports from the October 31 settlement date and have compared them to…

Paul Ausick | Oct 29, 2013 at 8:00 AM EDT

Pfizer Continues to Shrink

Wikimedia CommonsPfizer Inc. (NYSE: PFE) reported third-quarter 2013 results before markets opened Tuesday morning. The drug maker posted adjusted diluted…

Jon C. Ogg | Oct 28, 2013 at 1:19 PM EDT

Merck Sets Low Earnings Bar for Pfizer

The drug patent cliff for Big Pharma is coming with some continued consequences, and two drug giants with earnings this…

Douglas A. McIntyre | Oct 28, 2013 at 6:46 AM EDT

A New Rise in Global Mergers/Buyouts

courtesy of Verizon WirelessMergers and acquisitions (M&A) sometimes can be an excellent measure of the economy’s financial health. However, since…

Jon C. Ogg | Oct 27, 2013 at 8:38 AM EDT

The 10 Most Important Earnings in the Week Ahead

Jon OggEarnings season is in full swing and this coming week will bring many key earnings reports. This will also…

Jon C. Ogg | Oct 25, 2013 at 8:50 AM EDT

Short Sellers Abandoning Bets Against High-Yield Defensive Dividend Stocks

Jon OggWe have seen the short interest reports for the October 15 settlement date. It turns out that short sellers…

Paul Ausick | Oct 10, 2013 at 10:20 AM EDT

High-Yield Dividend Stocks Face Rising Short Interest

ThinkstockShort sellers have increased their bets against the stable high-dividend stocks that are in most Americans’ retirement accounts and mutual…

Jon C. Ogg | Oct 9, 2013 at 8:15 AM EDT

Credit Suisse Major Drug Stocks to Buy for Great Gains Ahead

ThinkstockThe drug and pharmaceutical sector is supposed to be a defensive one by nature, even if this week’s government shutdown…

Jon C. Ogg | Oct 2, 2013 at 12:25 PM EDT

Spin-Offs Back in Vogue: Six Must-Watch Special Situations

ThinkstockWhen the markets go through periods of great gains, it is not uncommon to see companies start to take more…

Douglas A. McIntyre | Oct 2, 2013 at 6:30 AM EDT

Big Pharma and 100,000 Jobs at Risk

ThinkstockMerck & Co. (NYSE: MRK) announced it would rid itself of 8,500 workers, many of whom work in the big…

Jon C. Ogg | Sep 30, 2013 at 10:35 AM EDT

Five FDA Approvals and Reviews at Risk Under a Government Shutdown

via Wikimedia CommonsIt looks like Congress and the president still cannot figure out how to play well with each other,…

Jon C. Ogg | Sep 25, 2013 at 9:40 AM EDT

Short Sellers Pile On and Attack High-Yield Dividend Stocks

ThinkstockShort sellers have increased their bets against the stable high-dividend stocks that are in most Americans’ retirement accounts and mutual…

1 … 67 68 69 70 71 … 98

Pfizer : PFE

All Pfizer Articles

Meet the Preliminary 2014 Dogs of the Dow: Dividends Galore

Top Analyst Upgrades and Downgrades: Apple, 3D Systems, Micron, Tesla and More

The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years

Short Sellers Made Big Changes in High-Yield Dividend Stocks

Pfizer Continues to Shrink

Merck Sets Low Earnings Bar for Pfizer

A New Rise in Global Mergers/Buyouts

The 10 Most Important Earnings in the Week Ahead

Short Sellers Abandoning Bets Against High-Yield Defensive Dividend Stocks

High-Yield Dividend Stocks Face Rising Short Interest

Credit Suisse Major Drug Stocks to Buy for Great Gains Ahead

Spin-Offs Back in Vogue: Six Must-Watch Special Situations

Big Pharma and 100,000 Jobs at Risk

Five FDA Approvals and Reviews at Risk Under a Government Shutdown

Short Sellers Pile On and Attack High-Yield Dividend Stocks

3 Biotech Stocks to Watch for Respectable Growth Beyond AI

Jill Schlesinger Greenlights $2.9M Retiree’s $200K Gift to Sons: ‘I Can’t Believe I’m Being the Dream Maker’

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

Jill Schlesinger Greenlights $2.9M Retiree's $200K Gift to Sons: 'I Can't Believe I'm Being the Dream Maker'

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

3 Biotech Stocks to Watch for Respectable Growth Beyond AI

Jill Schlesinger Greenlights $2.9M Retiree’s $200K Gift to Sons: ‘I Can’t Believe I’m Being the Dream Maker’

Pfizer : PFE

All Pfizer Articles

Meet the Preliminary 2014 Dogs of the Dow: Dividends Galore

Top Analyst Upgrades and Downgrades: Apple, 3D Systems, Micron, Tesla and More

The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years

Short Sellers Made Big Changes in High-Yield Dividend Stocks

Pfizer Continues to Shrink

Merck Sets Low Earnings Bar for Pfizer

A New Rise in Global Mergers/Buyouts

The 10 Most Important Earnings in the Week Ahead

Short Sellers Abandoning Bets Against High-Yield Defensive Dividend Stocks

High-Yield Dividend Stocks Face Rising Short Interest

Credit Suisse Major Drug Stocks to Buy for Great Gains Ahead

Spin-Offs Back in Vogue: Six Must-Watch Special Situations

Big Pharma and 100,000 Jobs at Risk

Five FDA Approvals and Reviews at Risk Under a Government Shutdown

Short Sellers Pile On and Attack High-Yield Dividend Stocks

3 Biotech Stocks to Watch for Respectable Growth Beyond AI

Jill Schlesinger Greenlights $2.9M Retiree’s $200K Gift to Sons: ‘I Can’t Believe I’m Being the Dream Maker’

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

Featured Reads

Jill Schlesinger Greenlights $2.9M Retiree's $200K Gift to Sons: 'I Can't Believe I'm Being the Dream Maker'

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts